Blood pressure and metabolic outcomes after efavirenz- or dolutegravir-based therapy started in acute HIV infection. Chan P, Moreland S, Sacdalan C, Colby DJ, et al. HIV Med 2025;26:1619-1625.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chan P, Moreland S, Sacdalan C, Colby DJ, et al. Blood pressure and metabolic outcomes after efavirenz- or dolutegravir-based therapy started in acute HIV infection. HIV Med 2025;26:1619-1625.
PMID: 41047593